The company's financial foundation is severely compromised, evidenced by a current ratio of 0.50 and total debt of $34.3 million against a negative equity position of $14.2 million.
| Total Current Assets | 20.21M | 20.34M | 32.2M | 27.96M | 22.32M | 28.43M | 17.79M | 9.52M | 8.15M | 3.8M | 2.56M | 8.45M | 4.88M |
| Cash & Short-Term Investments | 7.28M | 968K | 8M | 6.47M | 5.47M | 17.05M | 8.09M | 3.5M | 2.57M | 520.7K | 950.98K | 7.7M | 2.1M |
| Cash Only | 7.28M | 968K | 8M | 6.47M | 5.47M | 17.05M | 8.09M | 3.5M | 2.57M | 520.7K | 950.98K | 7.7M | 2.1M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 280K | 1.7M | 1.65M | 2.18M | 2.47M | 2.14M | 4.56M | 1.69M | 1M | 469.04K | 304.61K | 59.07K | 1.25M |
| Days Sales Outstanding | 14.6 | 53.84 | 51.43 | 81.67 | 75.31 | 180.52 | 177.35 | 107.07 | 82.8 | 39.26 | 785.62 | 83.44 | - |
| Inventory | 7.82M | 8.6M | 10.35M | 9.19M | 7.02M | 4.9M | 2.78M | 2.13M | 3.34M | 2.07M | 412.75K | 229.87K | 198.03K |
| Days Inventory Outstanding | 780.18 | 831.65 | 1.93K | 1.65K | 1.27K | 766.61 | 309.58 | 203.64 | 441.07 | 859.35 | 2.9K | 679.61 | - |
| Other Current Assets | 4.83M | 9.08M | 12.2M | 10.12M | 7.36M | 0 | 0 | 941K | 6.12K | 239.17K | 584K | 143.23K | 2.57M |
| Total Non-Current Assets | 17.22M | 17.98M | 21.23M | 22.8M | 25.13M | 24.83M | 25.05M | 26.89M | 32.89M | 39.83M | 1.01M | 3.95M | 872.52K |
| Property, Plant & Equipment | 1.5M | 1.46M | 1.4M | 1.67M | 1.7M | 1.73M | 677K | 710K | 760.62K | 1.22M | 885.95K | 829.23K | 872.52K |
| Fixed Asset Turnover | 19.42x | 7.87x | 8.35x | 5.84x | 7.05x | 2.50x | 13.86x | 8.13x | 5.81x | 3.57x | 0.16x | 0.31x | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.21M | 0 | 0 | 0 |
| Intangible Assets | 15.55M | 16.02M | 18.48M | 20.12M | 22.44M | 22.65M | 24.34M | 26.02M | 31.71M | 33.4M | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3M | 0 |
| Other Non-Current Assets | 169K | 494K | 1.35M | 1.01M | 995K | 446K | 37K | 154K | 420.83K | 0 | 122.16K | 122.16K | 0 |
| Total Assets | 37.43M | 38.32M | 53.42M | 50.76M | 47.45M | 53.27M | 42.84M | 36.41M | 41.04M | 43.63M | 3.56M | 12.41M | 5.76M |
| Asset Turnover | 0.68x | 0.30x | 0.22x | 0.19x | 0.25x | 0.08x | 0.22x | 0.16x | 0.11x | 0.10x | 0.04x | 0.02x | - |
| Asset Growth % | -92.37% | -28.27% | 5.24% | 6.98% | -10.91% | 24.33% | 17.67% | -11.29% | -5.93% | 1124.46% | -71.28% | 115.49% | - |
| Total Current Liabilities | 40.69M | 40.65M | 19.7M | 13.99M | 30.34M | 15.47M | 13.22M | 15.39M | 26.66M | 15.39M | 4.19M | 3.91M | 2.79M |
| Accounts Payable | 4.96M | 8.69M | 5.29M | 4.97M | 5.81M | 4.93M | 4.76M | 5.35M | 5.41M | 7.35M | 517K | 574.46K | 698.32K |
| Days Payables Outstanding | 592.97 | 840.06 | 986.9 | 891.27 | 1.05K | 771.15 | 529.58 | 511.92 | 714.53 | 3.05K | 3.63K | 1.7K | - |
| Short-Term Debt | 31.55M | 27.44M | 12.04M | 4.87M | 15.88M | 3.18M | 3.79M | 6.78M | 16.08M | 5.42M | 2.07M | 1.86M | 816.72K |
| Deferred Revenue (Current) | 510K | 170K | 170K | 0 | 0 | 0 | 0 | 0 | 4.94M | 177.39K | 224.45K | 251.94K | 23.8K |
| Other Current Liabilities | 168K | 0 | 0 | 0 | 0 | 1K | 179K | 3K | 373.83K | 2.17M | 1.16M | 468.7K | -88.01K |
| Current Ratio | 0.50x | 0.50x | 1.63x | 2.00x | 0.74x | 1.84x | 1.35x | 0.62x | 0.31x | 0.25x | 0.61x | 2.16x | 1.75x |
| Quick Ratio | 0.30x | 0.29x | 1.11x | 1.34x | 0.50x | 1.52x | 1.14x | 0.48x | 0.18x | 0.11x | 0.51x | 2.10x | 1.68x |
| Cash Conversion Cycle | 201.81 | 45.43 | 995.95 | 836.93 | 295.15 | 175.98 | -42.65 | -201.21 | -190.66 | -2.15K | 53.41 | -935.34 | - |
| Total Non-Current Liabilities | 12.5M | 16.36M | 27.23M | 31.88M | 18.47M | 25.94M | 12.42M | 10.35M | 9M | 10.98M | 1.82M | 4.1M | 1.88M |
| Long-Term Debt | 11.07M | 15.08M | 23.5M | 30.99M | 17.74M | 25.02M | 12.42M | 450K | 0 | 10.98M | 1.82M | 4.1M | 0 |
| Capital Lease Obligations | 3.67M | 892K | 686K | 886K | 725K | 919K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.32K | 0 |
| Other Non-Current Liabilities | 187K | 0 | 2.48M | 0 | 0 | 0 | 0 | 9.89M | 0 | 0 | 6.96K | 3.32K | 1.88M |
| Total Liabilities | 53.19M | 57.01M | 46.93M | 45.87M | 48.81M | 41.41M | 25.64M | 25.74M | 35.66M | 26.37M | 6.02M | 8.01M | 4.66M |
| Total Debt | 34.31M | 43.61M | 36.53M | 37.09M | 34.84M | 29.36M | 16.21M | 7.57M | 16.08M | 16.41M | 3.89M | 5.95M | 728.71K |
| Net Debt | 27.03M | 42.64M | 28.52M | 30.63M | 29.37M | 12.31M | 8.12M | 4.07M | 13.52M | 15.88M | 2.94M | -1.74M | -1.37M |
| Debt / Equity | -2.18x | - | 5.62x | 7.57x | - | 2.48x | 0.94x | 0.71x | 2.99x | 0.95x | - | 1.35x | 0.66x |
| Debt / EBITDA | -1.36x | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -1.07x | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -51.20x | -565.60x | -168.92x | -5.31x | -2.80x | -5.25x | -11.11x | -5.72x | -11.23x | -12.50x | -13.79x | -3.91x | - |
| Total Equity | -15.75M | -18.69M | 6.49M | 4.9M | -1.36M | 11.85M | 17.2M | 10.67M | 5.38M | 17.26M | -2.45M | 4.4M | 1.1M |
| Equity Growth % | -2516.23% | -387.77% | 32.61% | 461.14% | -111.44% | -31.1% | 61.17% | 98.27% | -68.81% | 803.33% | -155.79% | 301.29% | - |
| Book Value per Share | -30.54 | -280.43 | 771.72 | 11144.78 | -54279.21 | 999999.00 | 999999.00 | - | - | - | - | - | - |
| Total Shareholders' Equity | -14.18M | -17.29M | 7.29M | 4.96M | -657K | 11.61M | 17.2M | 10.67M | 5.38M | 17.26M | -2.45M | 4.4M | 1.1M |
| Common Stock | 1K | 1K | 0 | 0 | 0 | 0 | 4K | 5K | 6.49K | 10.53K | 1.4K | 812 | 525 |
| Retained Earnings | -391.07M | -399.92M | -346.48M | -308.25M | -266.95M | -219.49M | -166.9M | -133.09M | -94.55M | -62.4M | -40.44M | -25.7M | -11.09M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.24M | -833K | -467K | -652K | -680K | 0 | 0 | 0 | -9T | -43.63T | -3.56T | -12.41B | 0 |
| Minority Interest | -1.57M | -1.4M | -791K | -64K | -699K | 242K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity and insolvency
As reported in recent financial statements, Jaguar Health's total equity has deteriorated into a negative position of $14.2 million by 2026Q1, reflecting a consistent trend of capital erosion that signals a weakening financial foundation as the company struggles to achieve commercial scale for its botanical pipeline.
The shift from positive equity in previous periods to a deficit suggests that cumulative losses have now fully exhausted the company's book value. This trajectory implies that the business model is currently unable to generate sufficient internal capital to offset its ongoing research and development expenditures.
Based on the most recent quarterly data, the company's cash reserves have plummeted to $968,000, resulting in a current ratio of 0.50 that indicates an inability to cover short-term obligations without immediate and likely dilutive external financing to sustain its ongoing clinical trial operations.
A current ratio of 0.50 is a significant red flag, suggesting that current liabilities far exceed the liquid assets available to satisfy them. Investors should monitor this closely, as the lack of a liquidity buffer leaves the company with virtually no margin for error regarding its operational cash burn.
According to the provided balance sheet data, Jaguar Health carries $34.3 million in total debt as of 2026Q1, a figure that remains disproportionately high relative to the company's minimal cash position and negative equity, highlighting a precarious capital structure that limits future financing options.
The presence of significant debt on a balance sheet with negative equity suggests that the company is heavily reliant on external creditors to fund its survival. This leverage profile may complicate future efforts to raise capital, as potential investors may be deterred by the existing debt overhang.
As evidenced by the company's reported figures, goodwill accounts for $15.6 million of the $37.4 million in total assets, indicating that a substantial portion of the asset base is non-tangible and potentially subject to future impairment charges if commercial milestones for crofelemer are not met.
The heavy reliance on goodwill within the asset mix suggests that the balance sheet is sensitive to the company's ability to successfully commercialize its pipeline. If the expected economic benefits of these intangible assets fail to materialize, the company may be forced to recognize significant write-downs.
Quick answers to the most common questions about buying JAGX stock.
As of 2025, Jaguar Health, Inc. (JAGX) had total assets of $38.3M including $20.3M in current assets.
Jaguar Health, Inc. (JAGX) carries total debt of $43.6M, offset by $1.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Jaguar Health, Inc. (JAGX) has total shareholders' equity (book value) of $-17.3M ($-280.43 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Jaguar Health, Inc. (JAGX) reported a current ratio of 0.50x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.